• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SCIEX Sets a New Standard in Accurate Mass Quantitation With the ZenoTOF 8600 System and New Software Collaborations

    6/2/25 7:00:00 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials
    Get the next $DHR alert in real time by email

    At ASMS 2025, SCIEX, a global leader in life science analytical technologies and operating company of Danaher Corporation (NYSE:DHR), launches the ZenoTOF 8600 system, setting a new standard in accurate mass quantitation. The system is competitive in identification, superior in quantitation, and enhances structural understanding so scientists can now confidently quantify thousands of species from complex samples in short acquisition times.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250602013425/en/

    SCIEX launches the ZenoTOF 8600 system.

    SCIEX launches the ZenoTOF 8600 system.

    The ZenoTOF 8600 system brings sensitive quantitation and decades of SCIEX leadership in triple quad innovation to the ZenoTOF portfolio. Innovations include:

    • The OptiFlow Pro source, DJet ion guide, and QJet ion guide – Enables the system to generate and transmit more ions. When combined with the Zeno trap, this facilitates 10x improvement in sensitivity, compared to the ZenoTOF 7600+ system.
    • Mass Guard technology, introduced last year on the SCIEX 7500+ system – Protects the system from contamination and increases uptime.
    • New optical detector – Allows the system to operate effectively at higher ion currents.
    • ZT Scan DIA 2.0 – Covers a larger mass range so scientists can now quantify what was previously a struggle to identify – across all omics disciplines. ZT Scan DIA 2.0 is a transformation of the most comprehensive SCIEX DIA approach.

    "The ZenoTOF 8600 system gives you the resolution and speed you need, but the sensitivity allows us to do everything on one box. We are not just seeing more things, we are identifying them, and at times 30-40% more. And because of ZT Scan DIA 2.0, there is this additional treasure of information that has increased our capacity to discover new things, which we were not anticipating. It's the first time I've been able to do nominal mass resolution on the precursor, which finally allows us to do SWATH type of analysis on lipids or complex natural products," said Dr. Nicola Zamboni, Ph.D., Principal investigator and adjunct professor at the Institute of Molecular Systems Biology of ETH Zurich. "As a result, these abilities enhance our capacity in discovery biology. They deepen our understanding of mechanisms. They help us find things that matter."

    To match the data processing needs of the ZenoTOF 8600 system, the new SCIEX OS software version 4.0 enhances operability with speed and automation. Automated workflow improvements and progressive software functionalities establish the benchmark for efficiency, accuracy, and precision.

    This builds on the SCIEX OS ecosystem, to seamlessly connect innovations in hardware and software processing. A new software collaboration this year includes that with MS-Dial, an open-source software platform designed for untargeted metabolomics and lipidomics analysis. This collaboration enhances the identification and quantification of small molecules through advanced spectral deconvolution and library matching. The latest version of MS-Dial now supports SCIEX raw data across multiple scan modes and is well-suited for ZT Scan DIA, ensuring greater accuracy and efficiency in data analysis.

    In addition, SCIEX and Bioinformatics Solutions Inc (BSI) continue to drive innovation in mass spectrometry-based proteomics solutions. The latest release of PEAKS Studio 13 translates data from ZT Scan DIA, SWATH DIA, and DDA to deliver expansive peptide identification, reliable protein inference, and novel peptides, as well as deep insight into the PTM and sequence variant expression within biological studies. This version also brings processing improvements for ZT Scan DIA, optimizing CV% and processing speed to ensure greater accuracy and efficiency in proteomics workflows.

    "This year's launches will enable us to see exciting impact across OMICS research. We are motivated by what our customers tell us, that they can foresee real-world outcomes as a result of the new data generated and the insights interpreted," Jose Castro-Perez Ph.D., Vice president, product management at SCIEX.

    To learn more about the ZenoTOF 8600 system, visit https://sciex.com/products/mass-spectrometers/qtof-systems/8600-system.

    About SCIEX

    SCIEX empowers our customers to solve the most impactful analytical challenges in quantitation and characterization. With groundbreaking innovation and outstanding reliability and support, SCIEX has been at the forefront of the field for over 50 years. ​

    Since the launch of the first-ever commercially successful triple quadrupole in 1981, we continue to develop technologies and solutions that influence life-changing research and outcomes. That's why thousands of life science experts around the world choose SCIEX to get the answers they can trust. ​

    Advances in human wellness depend on the power of precise science.​

    For more information, visit sciex.com. ​

    Connect with us on LinkedIn, Facebook, X (Twitter) and Instagram.​

    SCIEX is proud to be part of Danaher. ​

    Danaher's science and technology leadership puts SCIEX solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers. Together with Danaher's other businesses across Biotechnology, Diagnostics and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day.

    The SCIEX clinical diagnostic portfolio is for in vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to www.sciex.com/diagnostics. All other products are For Research Use Only. Not for use in Diagnostic Procedures.

    Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries (see www.sciex.com/trademarks).

    © 2025 DH Tech. Dev. Pte. Ltd. MKT-35293-A.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250602013425/en/

    Lulu VanZandt

    Senior manager, brand, public relations and social media

    [email protected]

    M: +1 (508) 782-9484

    Get the next $DHR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DHR

    DatePrice TargetRatingAnalyst
    7/11/2025$275.00Sector Perform → Sector Outperform
    Scotiabank
    4/10/2025$205.00Equal Weight → Overweight
    Barclays
    3/21/2025$260.00Neutral → Buy
    Goldman
    3/14/2025$260.00Hold → Buy
    Stifel
    2/3/2025Outperform → Mkt Perform
    Raymond James
    12/23/2024Sector Perform
    Scotiabank
    12/19/2024$275.00Buy
    Guggenheim
    12/13/2024$290.00Neutral → Buy
    BofA Securities
    More analyst ratings

    $DHR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AstroNova Appoints Jorik E. Ittmann as President and Chief Executive Officer

    Leverages Mr. Ittmann's extensive print industry and international business experience Padraig Finn, with over 16 years in the print industry, promoted to Senior Vice President, Product Identification Tom Carll, Senior Vice President, Aerospace, Thomas DeByle, CFO, and Michael Natalizia, Chief Technology Officer, round out the Executive Leadership Team Darius G. Nevin appointed Executive Chairman AstroNova, Inc. (NASDAQ:ALOT), a leading innovator in specialized print technology solutions that enable data visualization, today announced that the Board of Directors has promoted Jorik E. Ittmann to President and CEO and appointed him to the Board of Directors, both to be effective

    8/4/25 9:00:00 AM ET
    $ALOT
    $DHR
    $VLTO
    Computer peripheral equipment
    Technology
    Industrial Machinery/Components
    Industrials

    Danaher Appoints Jonathan Leiken as General Counsel

    WASHINGTON, July 31, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a leading global life sciences and diagnostics innovator, today announced that Jonathan Leiken has been appointed Senior Vice President and General Counsel, effective August 25, 2025. Mr. Leiken will report directly to President and Chief Executive Officer Rainer Blair and will serve as an executive officer and a member of the Danaher Leadership Team. Jonathan Leiken succeeds Brian Ellis, who will retire after nearly a decade of distinguished service as Danaher's General Counsel. Mr. Ellis will remain at Danaher in an executive officer role through February 2026 to support the transition. "Jon brings nearly three deca

    7/31/25 4:15:00 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Danaher Announces Transition Plan for Chief Financial Officer

    WASHINGTON, July 22, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a leading global life sciences and diagnostics innovator, today announced that Matthew Gugino, currently Group Chief Financial Officer of the Company's Life Sciences Innovations Group and Vice President of Financial Planning & Analysis, will succeed Matthew McGrew as Danaher's Chief Financial Officer effective February 28th, 2026. Following the transition and consistent with past practice, Mr. McGrew will continue thereafter as an Executive Vice President of the Company, as he begins a gradual transition to retirement, after more than 20 years with Danaher. "Matt McGrew's financial leadership over the past two decades

    7/22/25 6:02:00 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    $DHR
    SEC Filings

    View All

    Danaher Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - DANAHER CORP /DE/ (0000313616) (Filer)

    7/31/25 4:31:51 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Danaher Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - DANAHER CORP /DE/ (0000313616) (Filer)

    7/24/25 4:50:27 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    SEC Form 10-Q filed by Danaher Corporation

    10-Q - DANAHER CORP /DE/ (0000313616) (Filer)

    7/21/25 6:39:11 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    $DHR
    Leadership Updates

    Live Leadership Updates

    View All

    AstroNova Appoints Jorik E. Ittmann as President and Chief Executive Officer

    Leverages Mr. Ittmann's extensive print industry and international business experience Padraig Finn, with over 16 years in the print industry, promoted to Senior Vice President, Product Identification Tom Carll, Senior Vice President, Aerospace, Thomas DeByle, CFO, and Michael Natalizia, Chief Technology Officer, round out the Executive Leadership Team Darius G. Nevin appointed Executive Chairman AstroNova, Inc. (NASDAQ:ALOT), a leading innovator in specialized print technology solutions that enable data visualization, today announced that the Board of Directors has promoted Jorik E. Ittmann to President and CEO and appointed him to the Board of Directors, both to be effective

    8/4/25 9:00:00 AM ET
    $ALOT
    $DHR
    $VLTO
    Computer peripheral equipment
    Technology
    Industrial Machinery/Components
    Industrials

    Danaher Appoints Jonathan Leiken as General Counsel

    WASHINGTON, July 31, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a leading global life sciences and diagnostics innovator, today announced that Jonathan Leiken has been appointed Senior Vice President and General Counsel, effective August 25, 2025. Mr. Leiken will report directly to President and Chief Executive Officer Rainer Blair and will serve as an executive officer and a member of the Danaher Leadership Team. Jonathan Leiken succeeds Brian Ellis, who will retire after nearly a decade of distinguished service as Danaher's General Counsel. Mr. Ellis will remain at Danaher in an executive officer role through February 2026 to support the transition. "Jon brings nearly three deca

    7/31/25 4:15:00 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Danaher Appoints Martin Stumpe as Chief Technology and AI Officer

    WASHINGTON, June 27, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR), a leading global life sciences and diagnostics innovator, today announced that Martin Stumpe will be appointed Chief Technology and AI Officer, effective October 1, 2025. He will report directly to Rainer Blair, President and Chief Executive Officer. This appointment marks a pivotal step in Danaher's digital transformation and its ambition to lead the next era of innovation in life sciences and diagnostics. Under Dr. Stumpe's leadership, Danaher will seek to accelerate the integration of AI across its global businesses—unlocking new levels of scientific discovery, operational efficiency and clinical impact. "Danaher i

    6/27/25 7:35:00 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    $DHR
    Financials

    Live finance-specific insights

    View All

    Danaher Reports Second Quarter 2025 Results

    WASHINGTON, July 22, 2025 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) (the "Company") today announced results for the quarter ended June 27, 2025. Key Second Quarter 2025 Results Net earnings were $555 million, or $0.77 per diluted common share and non-GAAP adjusted diluted net earnings per common share were $1.80.Revenues increased 3.5% year-over-year to $5.9 billion and non-GAAP core revenue increased 1.5% year-over-year.Operating cash flow was $1.3 billion and non-GAAP free cash flow was $1.1 billion.Rainer M. Blair, President and Chief Executive Officer, stated, "Our team's strong execution using the Danaher Business System, paired with another quarter of robust growth in our Bioproc

    7/22/25 6:00:00 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Danaher Schedules Second Quarter 2025 Earnings Conference Call

    WASHINGTON, June 17, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2025 on Tuesday, July 22, 2025 beginning at 8:00 a.m. ET and lasting approximately one hour. During the call, the company will discuss its financial performance, as well as future expectations. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call. You

    6/17/25 4:30:00 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Danaher Announces Quarterly Dividend

    WASHINGTON, May 6, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.32 per share of its common stock, payable on July 25, 2025 to holders of record on June 27, 2025. ABOUT DANAHERDanaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and h

    5/6/25 4:15:00 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    $DHR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Danaher Corporation (Amendment)

    SC 13G/A - DANAHER CORP /DE/ (0000313616) (Subject)

    2/9/23 11:16:32 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    SEC Form SC 13G/A filed by Danaher Corporation (Amendment)

    SC 13G/A - DANAHER CORP /DE/ (0000313616) (Subject)

    2/9/22 3:43:35 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    SEC Form SC 13D/A filed by Danaher Corporation (Amendment)

    SC 13D/A - DANAHER CORP /DE/ (0000313616) (Subject)

    11/2/21 9:29:29 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    $DHR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Zerhouni Elias A.

    4 - DANAHER CORP /DE/ (0000313616) (Issuer)

    7/28/25 5:07:48 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    SEC Form 4 filed by Director Stevens Raymond C

    4 - DANAHER CORP /DE/ (0000313616) (Issuer)

    7/28/25 5:07:00 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    SEC Form 4 filed by Director Spoon Alan G

    4 - DANAHER CORP /DE/ (0000313616) (Issuer)

    7/28/25 5:06:32 PM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    $DHR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Danaher upgraded by Scotiabank with a new price target

    Scotiabank upgraded Danaher from Sector Perform to Sector Outperform and set a new price target of $275.00

    7/11/25 7:56:02 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Danaher upgraded by Barclays with a new price target

    Barclays upgraded Danaher from Equal Weight to Overweight and set a new price target of $205.00

    4/10/25 8:28:29 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials

    Danaher upgraded by Goldman with a new price target

    Goldman upgraded Danaher from Neutral to Buy and set a new price target of $260.00

    3/21/25 8:01:35 AM ET
    $DHR
    Industrial Machinery/Components
    Industrials